ak-7

AK-7 is a brain-permeable SIRT2 inhibitor and to characterize its cholesterol-reducing properties in neuronal models with an IC50 of 15.5 μM.

TAK-715 is a p38 MAPK inhibitor for p38α.

TAK-778, a derivative of ipriflavone, demonstrates the ability to stimulate bone growth in both in vitro and in vivo models.

TAK-756 is a TAK1 inhibitor that selectively targets IRAK1 4 and exhibits excellent intra-articular pharmacokinetic properties. TAK1 is a potential molecular target for osteoarthritis (OA) due to its complementary anti-catabolic and anti-inflammatory effects.

TAK-700 salt is a potent and highly selective inhibitor of human 17,20-lyase with an IC50 of 38 nM and is over 1000-fold more selective than other CYPs such as 11-hydroxylase and CYP3A4.

TAK-700 (Orteronel) (Orteronel) is a potent and highly selective human 17, 20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). Phase 3.

AK-778-XXMU is an ID2 antagonist with a KD value of 129 nM.AK-778-XXMU has potential antitumor and anticancer activity and can be used for the study of gliomas.

TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1 2) with potential antineoplastic activity.

TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).

7-Bromohept-1-yne is a PROTAC Linker that can be used to synthesize AK-1690, a STAT6 (Signal transducer and activator of transcription 6) PROTAC degradator.